Two Sigma Investments, LP Avadel Pharmaceuticals PLC Transaction History

Two Sigma Investments, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$12.55 - $17.22 $150,487 - $206,485	-11,991 Reduced 16.07%	62,609 $1.06 Million
Q3 2023 Nov 14, 2023	SELL	$10.3 - $15.99 $2.62 Million - $4.06 Million	-254,204 Reduced 77.31%	74,600 $768,000
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $1.86 Million - $3.61 Million	219,243 Added 200.11%	328,804 $5.42 Million
Q1 2023 May 15, 2023	SELL	$6.41 - $9.95 $60,638 - $94,127	-9,460 Reduced 7.95%	109,561 $1 Million
Q4 2022 Feb 14, 2023	SELL	$5.02 - $10.0 $531,833 - $1.06 Million	-105,943 Reduced 47.09%	119,021 $852,000
Q3 2022 Nov 14, 2022	SELL	$2.57 - $7.31 $626,039 - $1.78 Million	-243,595 Reduced 51.99%	224,964 $1.13 Million
Q2 2022 Aug 15, 2022	BUY	$1.07 - $6.95 $501,358 - $3.26 Million	468,559 New	468,559 $1.14 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.